ARS Pharmaceuticals Hits New 52-Week Low at $8.33

ARS Pharmaceuticals, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 8.33 on November 3, 2025. This decline marks a significant downturn for the company, which has seen its stock price drop by 4.96% over the past year, contrasting sharply with the S&P 500's performance of 19.89% during the same period.
The company's market capitalization stands at USD 1,057 million, but it has faced challenges reflected in its financial metrics. With a negative return on equity of -24.97% and a debt-to-equity ratio of -1.25, ARS Pharmaceuticals is navigating a difficult financial landscape. The stock's price-to-book ratio is 5.50, indicating a premium valuation relative to its book value.

Recent financial results have not been favorable, with the company reporting a significant operating loss of USD 47.33 million in the latest quarter. Additionally, raw material costs have surged by 29.47% year-over-year, further straining profitability. As ARS Pharmaceuticals continues to grapple with these issues, its performance remains below par both in the near term and over the long term.